Kornimate/medical-research-clean huggingface dataset:
genomic analysis of peritoneal mesothelioma by cgh arrays

Conditions: Peritoneal Mesothelioma

Summary: peritoneal mesothelioma is a rare disease representing one third of all mesothelioma and nothing is known about molecular characteristics of this disease. as main cancers, genetic heterogeneity is probable. this genomic profiling associates comparative genomic hybridization (cgh) array, bap1 sequencing and gene expression in order to discover a biomarker that could be used in the treatment of this rare disease. corresponding histopathological and immunohistochemical report as all clinical data are available. all data with be merged to underline a few genes of interest on which we will focus our next investigations. depending of our preliminary results, bap1 mutations are expected, as it was also described in pleural mesothelioma. mutations in oncogenic drivers that could be targeted by specific therapy will be on particular interest in management of this rare disease with bad prognosis.


Eligibility criteria:
inclusion criteria: * surgical biopsy od the peritoneal tumor with frozen samples * age \> 18 years old exclusion criteria: * absence of peritoneal mesothelioma * absence of frozen samples

Keywords: mesothelioma peritoneum genomic cgh arrays
impact of an antioxidant alimentary complement on sperm data

Conditions: Infertility

Summary: male infertility is a multifactorial disease process with a number of potential contributive causes. considering the majority of male infertility cases are due to deficient sperm production of unknown origin, environmental and nutritional factors must be evaluated. the purpose of this study is to evaluate the effects of 6 months antioxidant dietary complement (conceptio) on sperm parameters (sperm count, motility and dna fragmentation) in infertile men with oligoasthenozoospermia.


Eligibility criteria:
inclusion criteria: * number of sperm cells \< 15m / ml and\\or mobility \< 40 %. * signature of a form of not opposition to the research. * membership in a social security system. exclusion criteria: * number of sperm cells = 100m / ml.

Keywords: male
analgesic efficacy and safety of v116517 in subjects with moderate to severe chronic pain due to osteoarthritis (oa) of the knee

Conditions: Osteoarthritis, Knee; Pain

Summary: the primary objective of this study is to evaluate the analgesic efficacy of 2 dose levels of v116517 versus placebo.


Eligibility criteria:
key inclusion criteria: 1. subjects with moderate pain due to oa of the knee as their primary pain condition. 2. subjects with diagnostic criteria for primary pain condition (american college of rheumatology \[acr\] clinical and radiographic criteria): * at least 1 of the following in addition to knee pain: age \>50, stiffness \<30 min, crepitus on active motion, and * kellgren-lawrence (k-l) grade ≥ 2 radiographic evidence within the past 2 years. key exclusion criteria: 1. subjects with chronic pain conditions other than oa of the knee as their predominant pain condition, including gout, pseudo gout, psoriatic arthritis, active lyme disease, rheumatoid arthritis or any other inflammatory arthritis, fibromyalgia, neuropathic pain conditions, bursitis, or acute injury or signs of active infection in the target pain area. 2. subjects who cannot or will not agree to stop all concomitant analgesic medications, apart from specified protocol supplemental analgesic medications. 3. subjects with history of seizures within the past 5 years. 4. subjects who use opioids more than 4 days per week. 5. pain-condition-specific exclusions: * subjects who received local pain-control procedures, including intra- articular steroid injection in the study knee or intramuscular steroid injection at any site within 6 weeks of entering the study or hyaluronate injection in the study knee within 12 weeks of entering the study. 6. subjects who have had arthroscopy on either knee or hip within 6 months of entering the study, or open surgery on either knee or hip within 12 months of entering the study. 7. active-comparator-related exclusions: * subjects who are allergic to or cannot tolerate naproxen or acetaminophen, including history of nsaid-induced asthma, or nasal polyps; * subjects with history of bleeding disorders or history of documented gastrointestinal ulcer disease. other protocol specific inclusion/exclusion criteria may apply.

Keywords: pain osteoarthritis knee
stereotactic body radiotherapy and concurrent cisplatin for re-irradiation of unresectable, recurrent squamous cell carcinomas of head and neck

Conditions: Squamous Cell Carcinoma of the Head and Neck

Summary: this study involves another course of radiation (called re-irradiation) to the participant's tumor. the type of radiation is called stereotactic body radiation therapy (sbrt). the purpose of this study is to compare the effects, good and/or bad, of different doses of sbrt given along with the chemotherapy drug, cisplatin. the researchers want to see which dose of radiation will work best in controlling the growth of head/neck cancer. the usual treatment for head/neck cancer that has grown is surgery and/or more radiation with various chemotherapy drugs.

stereotactic body radiation therapy (sbrt) is a relatively new radiation technique in which a few very high doses of radiation are delivered to small, well-defined tumors. it has been used effectively in other cancers like lung and liver. the goal is to deliver a radiation dose that is high enough to kill the cancer while limiting radiation to surrounding healthy organs. the daily dose of radiation is 2-3 times greater than conventional radiotherapy, but it is given for only 5 days over a 2 week period. conventional radiotherapy is given over 6-7 weeks. the chemotherapy drug, cisplatin is used as a radiation sensitizer and will be given before each of the 5 radiation treatments.

Eligibility criteria:
inclusion criteria: * recurrence of previously pathologically proven squamous cell carcinoma of the head and neck, including original primary sites in the paranasal sinuses, nasal cavity, nasopharynx, oropharynx, oral cavity, larynx, hypopharynx, salivary glands, and/or involvement of cervical lymph nodes * prior radiotherapy to doses ≥ 45 gy to the area of recurrence, ≥ 6 months prior to enrollment * eastern cooperative oncology group (ecog) performance status 0 - 2 * life expectancy \> 6 months * medically unfit for surgery or deemed surgically unresectable by head and neck (h\&n) surgeon within 60 days prior to enrollment, or patient refusal of surgery * normal organ and marrow function * no prior evidence of grade 3 or greater toxicity or neuropathy * medically fit to receive cisplatin exclusion criteria: * positive urine pregnancy test and/or breastfeeding. women of childbearing potential or sexually active males must be willing to use effective contraception throughout their participation in the treatment phase of the study. * evidence of distant metastases * tumor size \> 7 cm in one direction * tumor within 1 cm of the spinal cord * cardiac history: class iii or greater congestive heart failure (chf) or myocardial infarction (mi) within last 6 months * medical condition or social situation that at the discretion of the principal investigator (pi) would preclude them from completion of the trial

Keywords: squamous cell carcinoma head and neck cancer paranasal sinuses nasal cavity nasopharynx oropharynx oral cavity larynx hypopharynx salivary glands cervical lymph nodes
evaluation of dextenza in the management of pain and inflammation in patients with anterior uveitis compared to standard of care topical corticosteroids

Conditions: Non-infectious Anterior Uveitis

Summary: this a prospective study review of the clinical efficacy of dextenza for the treatment of anterior uveitis compared to the standard of care topical corticosteroid treatment

patients with anterior uveitis are typically treated aggressively with every 1-2 hour (while the patient is awake) potent topical steroid agents, during initial stage of inflammation, and evaluated at frequent intervals, with a schedule of steroid tapering dictated by clinical response. the most common topical corticosteroid prescribed for the treatment of anterior uveitis are prednisolone acetate 1%, dexamethasone 0.1%, prednisolone sodium phosphate 1% and difluprednate 0.05%. however, topical treatments are limited by the potential for patient non-adherence and variation in drug concentrations due to the intermittent or suspension of use nature of application. a corticosteroid insert placed in the inferior and superior canaliculi provides the advantages of reliable and continuous drug delivery for 24 hours a day for 30 days without the need for patients to adhere to a treatment regimen. dextenza is a sustained-release dexamethasone intracanalicular insert recently approved by the fda for pain and inflammation post ophthalmic surgery. dextenza was shown to decrease inflammation and pain compared with placebo following cataract surgery in a multicenter randomized clinical trial.

Eligibility criteria:
inclusion criteria: * \> 18 years old * active non-infectious anterior uveitis * able to provide signed written consent prior to participation in any study-related procedures. exclusion criteria: * have active intermediate, posterior uveitis, or panuveitis * have infectious anterior uveitis * have used topical corticosteroid treatment up to 48 hours prior to the baseline visit * have used oral corticosteroid within the past 14 days prior to baseline visit (patients using stable doses of inhaled corticosteroids for 30 days prior to baseline visit can be included in the study) * have received intravitreal or sub-tenon corticosteroid treatment prior to baseline visit or ozurdex ® in the study eye within the 6 months prior to the baseline visit * are currently using prescribed nonsteroidal anti-inflammatory agents or prescribed immunosuppressive agents, unless the dose has been stable for the last 6 weeks and no change in dosing is anticipated for the duration of the study * have severe/serious ocular pathology or medical condition which may preclude study completion * dacriocystitis * are pregnant or lactating female, or female of childbearing age using inadequate birth control method * have participated in another investigational device or drug study within 30 days of the baseline visit
prevalence of hepatomegaly in children and adolescents with type 1 diabetes mellitus

Conditions: Hepatomegaly

Summary: to assess the prevalence of hepatomegaly in children and adolescents with type 1 diabetes mellitus, and to find out it᾿s underlying etiology.

type 1 diabetes is a disorder of glucose metabolism that results from insulin deficiency secondary to autoimmune destruction of insulin-secreting β-cells. the prevalence of liver disease among diabetics is estimated to be between 17% and 100%(1). most of these data were obtained from studies of obese adults with non-insulin dependent diabetes(2). data regarding frequency of aetiological causes of hepatomegaly in children and adolescent with type 1 diabetes mellitus are scanty even in international publication(2). diabetes mellitus (dm) is associated with various structural and functional liver abnormalities, including non-alcoholic fatty liver disease (nafld) and hepatic glycogenosis (hg)(3). nafld represents the most common liver disease(3) and is more typically found in obese adults with t2dm secondary to insulin resistance, while (hg) is more common in patients with lower body mass index and pediatric patients(4). hg involves pathological glycogen storage in hepatocytes and is characterized by hepatomegaly and a transient elevation in liver transaminases that is associated with poorly controlled dm, particularly type 1 diabetes (t1d)(5). the differential diagnosis of hepatomegaly in diabetic patients must consider several other potential causes of liver damage, such as infection (e.g., viral hepatitis), metabolic disorders (e.g., α1-antitrypsin deficiency and wilson's disease), obstruction, autoimmune liver disease, hemochromatosis and celiac disease(6). presence of hepatomegaly and/or hyperechogenic liver on ultrasound abdomen was an indication for further laboratory work up to investigate other possible liver pathologies .the screening work up included: hbv surface antigen, anti-hcv antibody, serum immunoglobulins, anti-nuclear antibody, smooth muscle antibody qualitative test , serum ferritin, serum iron, transferring saturation, and total iron binding capacity, urine for organic acids and plasma for amino acids, to evaluate for possibility of viral hepatitis b and c, autoimmune liver disease, hemochromatosis, and metabolic disorder, respectively(7). it was considered that the finding of hyperechogenic liver and/or hepatomegaly on ultrasound and negative screening work up for underlying liver disease as consistent with a likely diagnosis of hepatic glycogenosis or less likely fatty liver(8).

Eligibility criteria:
inclusion criteria: * patients with type 1 diabetes mellitus diagnosed according to the diagnostic criteria of the american diabetes association 2011. exclusion criteria: - 1-patients with type 2 diabetes mellitus 2-patients with secondary diabetes 3-patients with type 1 diabetes mellitus with other system affection rather than hepatic affection like ( central nervous system, respiratory, renal, cardiovascular). 4- syndromic children. 5-patients known to have liver disease prior to diagnosis of diabetes.
pulmonary care and research collaborative patient registry

Conditions: Interstitial Lung Disease

Summary: the purpose of this research study is to build and maintain a registry of people with interstitial lung disease (ild). medical information collected for this registry may be used to advance ild and pulmonary research and improve patient care. this is an observational registry. participants will not receive any investigational treatments or investigational drugs as part of their participation in this registry.

the registry will contain longitudinal medical histories of ild patients. the creation and curation of the registry with utilize release of information services, biomedical informatics methods and human expert reviews. among the registry's long-term goals is to utilize its data and informatics resources to study and advance ild diagnosis and treatment. the registry will be developed with a set of capabilities to consistently, repeatedly, and economically build research-grade datasets that allow cohort development from natively unstructured and non-standard phenotypic clinical and imaging data.

Eligibility criteria:
inclusion criteria: * people with a confirmed diagnosis of interstitial lung disease by a primary care physician and/or pulmonologist. exclusion criteria: -

Keywords: progressive fibrosing interstitial lung disease idiopathic pulmonary fibrosis interstitial lung disease associated with systemic sclerosis myositis-associated interstitial lung disease sarcoidosis hypersensitivity pneumonitis pulmonary fibrosis
post-marketing surveillance on long term use of ofev capsules in systemic scleroderma associated interstitial lung disease (ssc-ild) in japan

Conditions: Lung Diseases, Interstitial

Summary: the primary objective is to confirm the incidence of adverse drug reactions (focus on gastrointestinal symptoms including diarrhoea and nausea) to ofev capsules seen in clinical trials with real world data generated in patients with ssc-ild.


Eligibility criteria:
inclusion criteria: * patients in japan with ssc-ild who are prescribed with ofev capsules and have never been treated with ofev capsules before enrolment will be included. exclusion criteria: * none.
seroquel xr in the long term treatment of schizophrenia

Conditions: Relapse in Schizophrenia

Summary: the purpose of the study is to determine whether the seroquel xr treatment for 6 months improves the relapse prevention in schizophrenic outpatients


Eligibility criteria:
inclusion criteria: * schizophrenic outpatients on at least 600 mg seroquel xr treatment for at least 1 month exclusion criteria: * severe cerebro- and cardiovascular disease, severe hepatic impairment, gravidity

Keywords: seroquel xr schizophrenia relapse prevention
remote ischemic preconditioning effect on postsurgical pain

Conditions: Pain

Summary: remote ischemic preconditioning (ripc) will improve the postoperative pain experience in patients undergoing abdominal surgery. although abdominal surgery can be a lifesaving procedure many people have a significant amount of postsurgical pain. severe postsurgical pain may lead to chronic pain in some people. "remote ischemic preconditioning" may reduce the amount of postsurgical pain. remote ischemic preconditioning is done by inflating a balloon (very similar to a blood pressure cuff) on the leg until it blocks blood flow for a few minutes. the cuff is then deflated and blood flow resumes. the process is repeated up to three times. this procedure causes the body to increase its natural pain relief system that may help to decrease the amount of postsurgical pain.


Eligibility criteria:
inclusion criteria: 1. ages 30-80 2. undergoing elective open intra-peritoneal surgery 3. able to provide written informed consent to participate 4. laparoscopic abdominal surgery exclusion criteria: 1. ongoing workman's compensation claim 2. \>50mg/day of oral morphine or morphine equivalent 3. currently being treated for lower extremity dvt 4. known intracranial hypertension (not excluding patients with a functioning vp shunt) 5. known hypercoagulable state (e.g. factor v leiden, protein s or c deficiency) 6. ongoing localized thigh pain 7. planned epidural analgesia 8. pregnancy 9. any dsm iv-r axis i psychotic disorders 10. unable to understand english 11. unable to understand the consent form

Keywords: remote ischemic preconditioning acute pain
the feasibility study for real-time remote ct reading for suspected acute appendicitis using iphone

Conditions: Telemedicine

Summary: 1. purpose - the investigators aim to evaluate the feasibility of iphone based remote control system as a real-time remote ct reading tool for suspected appendicitis under 3g network and the suboptimal illumination. 2. methods * a total of 120 abdominal ct examinations; sixty had no findings of appendicitis, while the other sixty showed signs of acute appendicitis, were selected. the 16 raters reviewed these images using an lcd monitor of the pacs workstation and also an iphone which was connected to the pacs workstation via remote control system, grading the probability of presence of acute appendicitis on each examination by a five likert scale. * the investigators will compare the diagnostic performance between two devices.

the 16 raters were randomly divided into two groups * the raters in group one reviewed the ct examinations numbered from one to 60 using lcd monitor and reviewed the remaining ct examinations numbered from 61 to 120 using iphone with teamviewer at their first visit * the other group firstly reviewed the ct scans numbered from one to 60 using iphone with teamviewer and 61 to 120 with the lcd monitor. * they visited twice with an interval of four weeks and reviewed the ct scans using revered devices at each session. * the raters were instructed to rate the likelihood of the presence or absence of appendicitis in each case using a five-likert scale (1 = obvious no appendicitis, 2 = unlikely appendicitis, 3 = unsure, 4 = likely appendicitis, 5 = obvious appendicitis).

Eligibility criteria:
inclusion criteria: * board certified emergency physicians with a clinical experience of 5 years and over. exclusion criteria: * corrected eyesight \< 20/30 * color weakness or blindness

Keywords: telemedicine appendicitis remote consultation
a study to investigate the clearance of pf-04776548 from the body following a very low (micro) dose of the compound using a low level of radiotracer to help quantify expected low concentrations of pf-04776548 in the body

Conditions: Human Immunodeficiency Virus (HIV)

Summary: to investigate the pharmacokinetics of pf-04776548 following administration of a micro-dose of pf-04776548 via both intravenous and oral routes.


Eligibility criteria:
inclusion criteria: * healthy male subjects between the ages of 18 and 65 years, inclusive (healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12-lead ecg and clinical laboratory tests). * body mass index (bmi) of 17.5 to 30.5 kg/m2; and a total body weight \>50 kg (110 lbs). exclusion criteria: * evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing). * any condition possibly affecting drug absorption (eg, gastrectomy). * a positive urine drug screen. * history of regular alcohol consumption exceeding 21 drinks/week (1 drink = 5 ounces (150 ml) of wine or 12 ounces (360 ml) of beer or 1.5 ounces (45 ml) of hard liquor) within 6 months of screening. * use of tobacco- or nicotine-containing products in excess of the equivalent of 5 cigarettes per day.

Keywords: micro-dose pharmacokinetics open label pf-04776548
carbon dioxide, oxygen and mean arterial pressure after cardiac arrest and resuscitation

Conditions: Out-of-Hospital Cardiac Arrest

Summary: the comacare trial is a pilot multicenter randomized trial to assess the feasibility and effect on brain injury markers of targeting low or high normal arterial oxygen tension (pao2), arterial carbon dioxide tension (paco2) and mean arterial pressure (map) in comatose, mechanically ventilated patients after out-of-hospital cardiac arrest. using factorial design, participants are randomized at admission to intensive care unit to one of eight groups targeting either low or high normal values of pao2, paco2 and map for 36 h. in this way, investigators will be assessing the feasibility and effect of all three variables at the same time. the primary outcome is serum concentration of neuron-specific enolase (nse) at 48 h after cardiac arrest. feasibility outcome is between-group separation in pao2, paco2 and map levels. secondary outcomes include continuous monitoring of cerebral oxygenation, eeg and ecg for 48 h, the levels of nse, s100b and cardiac troponin at randomization and 24, 48 and 72 h after cardiac arrest and neurological assessment at 6 months after cardiac arrest.


Eligibility criteria:
inclusion criteria: * witnessed out-of-hospital cardiac arrest with ventricular fibrillation (vf) or ventricular tachycardia (vt) as the initial rhythm * delay of return of spontaneous circulation (rosc) 10-45 min from the start of the arrest * confirmed or suspected cardiac origin * mechanical ventilation * markedly impaired level of consciousness (no response to verbal commands and glasgow coma scale \[gcs\] motor score \< 5) * deferred consent possible or likely * active intensive care initiated, including targeted temperature management (33-36 c) exclusion criteria: * probable withdrawal of active icu care due to terminal illness or poor prognosis because of severely reduced functional status before cardiac arrest * confirmed or suspected intracranial pathology and/or suspicion of raised intracranial pressure * pregnancy * severe oxygenation problem (pao2 / fio2 \< 100 mmhg) * severe copd

Keywords: out-of-hospital cardiac arrest resuscitation hypoxia-ischemia, brain